Biospecimen Collection Proteomic

生物样本采集蛋白质组学

• 批准号: 10040642
• 负责人: LEONARD FREEDMAND
• 金额: $ 548.12万
• 依托单位: LEIDOS BIOMEDICAL RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-08-31 至 2020-08-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10040642
• 关键词: Adherence; Blood; Collection; Colon Carcinoma; Malignant neoplasm of ovary; Morphologic artifacts; Normal tissue morphology; Proteomics; Standardization; The Cancer Genome Atlas; design; malignant breast neoplasm; prospective; tumor

Pre-analytical variables have the potential to significantly impact proteomic profiles. Furthermore, the annotations provided for the TCGA tumors do not include relevant information on such pre-analytical variables. To eliminate potential artifacts resulting from pre-analytic variables, a prospective collection of tumor, adjacent normal tissue, and blood from each of three tumor types, breast cancer, ovarian cancer and colon cancer, will be commenced. These collections will be performed under strict adherence to SOPs designed to minimize and standardize the effects of post-acquisition pre-analytical variables on proteomic profiles.

分析前变量有可能显著影响蛋白质组学图谱。此外，为TCGA肿瘤提供的注释不包括此类分析前变量的相关信息。为了消除分析前变量产生的潜在伪影，将开始前瞻性收集三种肿瘤类型（乳腺癌、卵巢癌和结肠癌）的肿瘤、相邻正常组织和血液。这些采集将严格按照SOP进行，旨在最大限度地减少和标准化采集后分析前变量对蛋白质组学谱的影响。